Serca Pharmaceuticals three main shareholders are:
The rest of the shares are distributed between several private investors, founders and management.
Serca Pharmaceuticals has been granted two projects by the Norwegian Research Council (NRC). The first project from 2019 – 2020 finished successfully and had subsidy framework of kr 5 million. The second project started October 2020 and will finish March 2023. The total budget for the project is kr 33 million and NRC will contribute with kr 16 million.
Serca Pharmaceuticals is also part of SkatteFUNN.